Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations.

Isabella P Godói,André S Santos,Francisco A Acurcio,Juliana Alvares,Edna A Reis,Cristina M R Brandão,Brian Godman,Augusto A Guerra Júnior,Livia L P Lemos

doi:10.3389/fphar.2017.00041

Abstract

Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research.Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine.Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil’s regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine.Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.

Highlights

Introduction and ObjectiveDengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide
This study estimated the willingness to pay of Brazilian consumers toward the CYD-TDV dengue vaccine through an analysis of contingent valuation, which enables evaluation of the monetary amount an individual is willing to pay to acquire a certain product or service using questionnaires with direct questions
Willingness to Pay for CYD-TDV Dengue Vaccine

Summary

Introduction

Introduction and ObjectiveDengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. The global annual incidence has been estimated at approximately 50 to 100 million symptomatic cases each year in recent years (Beatty et al, 2011; Bhatt et al, 2013) This flavivirus represents an important social and economic impact in most tropical and subtropical countries, and it is currently estimated that approximately US$5million are spent annually on hospitalizations related to dengue worldwide (Suaya et al, 2009). This is likely to be a considerable under-estimate. In 2014, more than 150 million Brazilian reais (US$42.016million) were spent on surveillance, prevention and control of dengue and chikungunya virus in Brazil (Brasil, 2014b)

Methods

Results

Discussion

Conclusion